Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in industry and research area. Creative Peptides is staffed by scientific teams with experts in the field of peptide technology, antibodies and synthetic chemistry. Our extensive expertise is translated into high quality products and world-class services to ensure the maximum satisfaction of the customs.
Featured Products:
>> API Peptides
>>Cosmetic Peptides
>>Catalog Peptides
Contact
https://www.creative-peptides.com/
17 Ramsey Road, Shirley, NY 11967, USA
Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch…
Christopher Posner, US head for Danish medical dermatology specialist LEO Pharma, outlines how a mid-sized European company navigates the US market’s complex access and affordability issues, the innovations that the…
Two leading executives in the US generics market outline why robust company culture is key to attracting top talent that might otherwise gravitate towards the traditional research-driven industry. Talent…
In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
As of 11 June 2020, there have been over two million confirmed cases of COVID-19 in the US and over 115,000 deaths, with the US having occupied the leading spot…
Peter L Saltonstall, president and CEO of the US National Organization for Rare Disorders (NORD) shares the organization’s key priorities, what makes NORD a unique patient advocacy group in the…
Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the…
At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack…
Jose Antonio Moreno Toscano, CEO for the US affiliate of iconic French firm LFB shares the company’s journey in the US market and his insights for other European mid-caps looking…
Dr Gerard Anderson of Johns Hopkins University Bloomberg School of Public Health critiques the US response to the COVID-19 pandemic, before explaining how access and affordability in the US can…
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
See our Cookie Privacy Policy Here
